The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes
Open accessAbstract
Imeglimin is an investigational first‐in‐class novel oral agent for the treatment of type 2 diabetes (T2D). Several pivotal phase III trials have been completed with evidence of statistically significant glucose lowering and a generally favourable safety and tolerability profile, including the lack of severe hypoglycaemia. Imeglimin's mechanism of action involves dual effects: (a) amplification of glucose‐stimulated insulin secretion (GSIS) and preservation of β‐cell mass; and (b) enhanced insulin action, including the potential for inhibition of hepatic glucose output and improvement in insulin signalling in both liver and skeletal muscle. At a cellular and molecular level, Imeglimin's underlying mechanism may involve correction of mitochondrial dysfunction, a common underlying element of T2D pathogenesis. It has been observed to rebalance respiratory chain activity (partial inhibition of Complex I and correction of deficient Complex III activity), resulting in reduced reactive oxygen species formation (decreasing oxidative stress) and prevention of mitochondrial permeability transition pore opening (implicated in preventing cell death). In islets derived from diseased rodents with T2D, Imeglimin also enhances glucose‐stimulated ATP generation and induces the synthesis of nicotinamide adenine dinucleotide (NAD + ) via the ‘salvage pathway’. In addition to playing a key role as a mitochondrial co‐factor, NAD + metabolites may contribute to the increase in GSIS (via enhanced Ca ++ mobilization). Imeglimin has also been shown to preserve β‐cell mass in rodents with T2D. Overall, Imeglimin appears to target a key root cause of T2D: defective cellular energy metabolism. This potential mode of action is unique and has been shown to differ from that of other major therapeutic classes, including biguanides, sulphonylureas and glucagon‐like peptide‐1 receptor agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931 · cited 1×
“24 weeks produced a significant effect on the Quantitative Insulin Sensitivity Check Index (QUICKI), a measure of insulin sensitivity that correlates with results from glucose clamp studies.(48) Specifically, mean QUICKI values were increased by 0.”
ResultMechanisms of Insulin Action and Insulin Resistance
Petersen, M. C., & Shulman, G. I. (2018) · Physiological Reviews · doi:10.1152/physrev.00063.2017 · Cited by 3,028
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
Self-citationReactive oxygen species have a causal role in multiple forms of insulin resistance
Houstis, N., Rosen, E. D., & Lander, E. S. (2006) · Nature · doi:10.1038/nature04634 · Cited by 2,525 · cited 1×
“tory chain also cause excessive reactive oxygen species (ROS) formation,(23) which has a clearly causative role in T2D pathophysiology.(27,28) Nicotinamide adenine dinucleotide (NAD) is a critical co-”
BackgroundThe mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157 · cited 1×
“Metformin is also known to inhibit gluconeogenesis via mild inhibition of Complex I.(54) In isolated rat hepatocytes, both Imeglimin and metformin inhibit gluconeogenesis; however, their effects on Complex I appear to be divergent.”
BackgroundMitochondrial dysfunction and type 2 diabetes
Lowell, B. B., & Shulman, G. I. (2005) · Science · doi:10.1126/science.1104343 · Cited by 2,070
Cantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648 · cited 2×
“In addition to its role to enhance mitochondrial function,(59) NAD is metabolized by CD38(60) to generate a second messenger, cyclic ADP-ribose (cADPR), which is implicated in enhancing Ca mobilization from intracellular stores via its interaction with the ryanodine receptor (RyR).(29,30,61) Increases in intracellular…”
BackgroundMetformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284
Anderson, E. J., Lustig, M. E., Boyle, K. E., Woodlief, T. L., Kane, D. A., Lin, C.-T., Price, J. W., Kang, L., Rabinovitch, P. S., Szeto, H. H., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37048 · Cited by 1,253
Nutrient-Sensitive Mitochondrial NAD+ Levels Dictate Cell Survival
Yang, H., Yang, T., Baur, J. A., Perez, E., Matsui, T., Carmona, J. J., Lamming, D. W., Souza-Pinto, N. C., Bohr, V. A., Rosenzweig, A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.035 · Cited by 950 · cited 1×
“Indeed, NAD depletion is known to potentiate apoptotic cell death,(66) whereas exogenous NAD is reportedly cytoprotective.(31,67)”
BackgroundIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
Metformin-associated lactic acidosis: current perspectives on causes and risk
DeFronzo, R., Fleming, G. A., Chen, K., & Bicsak, T. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.014 · Cited by 658 · cited 1×
“Increased plasma lactate and even lactic acidosis can occur rarely with metformin overdose or in the setting of renal failure.(56,57) Because inhibition of Complex I may contribute to this risk,(57) it is important to consider whether Imeglimin might lead to increases in”
BackgroundNAD+ homeostasis in health and disease
Katsyuba, E., Romani, M., Hofer, D., & Auwerx, J. (2020) · Nature Metabolism · doi:10.1038/s42255-019-0161-5 · Cited by 627
Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., & Polonsky, K. S. (1998) · Diabetes · doi:10.2337/diabetes.47.3.358 · Cited by 551
DeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Insulin resistance occurs in several tissues including skeletal muscle(10) and in the liver, where the effect of insulin to suppress glucose production is attenuated.(11) Deficient β-cell function is evident from a marked reduction in the acute insulin secretory response to glucose— both in vivo and in islets isolated…”
BackgroundSulfonylurea Stimulation of Insulin Secretion
Proks, P., Reimann, F., Green, N., Gribble, F., & Ashcroft, F. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s368 · Cited by 510
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetologia · doi:10.1007/s00125-019-05039-w · Cited by 487
Functional and Molecular Defects of Pancreatic Islets in Human Type 2 Diabetes
Del Guerra, S., Lupi, R., Marselli, L., Masini, M., Bugliani, M., Sbrana, S., Torri, S., Pollera, M., Boggi, U., Mosca, F., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.3.727 · Cited by 466
Maassen, J. A., ‘t Hart, L. M., van Essen, E., Heine, R. J., Nijpels, G., Jahangir Tafrechi, R. S., Raap, A. K., Janssen, G. M. C., & Lemkes, H. H. P. J. (2004) · Diabetes · doi:10.2337/diabetes.53.2007.s103 · Cited by 439
Metabolic Inflexibility: When Mitochondrial Indecision Leads to Metabolic Gridlock
Muoio, D. M. (2014) · Cell · doi:10.1016/j.cell.2014.11.034 · Cited by 438
Role of mitochondria in the mechanism(s) of action of metformin
Vial, G., Detaille, D., & Guigas, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00294 · Cited by 303
Self-citationDetaille, D., Vial, G., Borel, A.-L., Cottet-Rouselle, C., Hallakou-Bozec, S., Bolze, S., Fouqueray, P., & Fontaine, E. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2015.72 · Cited by 99
Self-citation
Cited by
Mitochondrial and metabolic dysfunction in ageing and age-related diseases
Amorim, J. A., Coppotelli, G., Rolo, A. P., Palmeira, C. M., Ross, J. M., & Sinclair, D. A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00626-7 · Cited by 990
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Nauck, M. A., Wefers, J., & Meier, J. J. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00113-3 · Cited by 289
NAD+ in COVID-19 and viral infections
Zheng, M., Schultz, M. B., & Sinclair, D. A. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.02.001 · Cited by 62
Omura, T., & Araki, A. (2022) · Geriatrics & Gerontology International · doi:10.1111/ggi.14339 · Cited by 47
Deshmukh, A., Chang, K., Cuala, J., Hernandez Campos, M. J., Mahmood, S., Verma, R., Georgia, S., Loconte, V., & White, K. L. (2025) · Structure · doi:10.1016/j.str.2025.07.022 · Cited by 9
Metadata
- Authors
- Hallakou‐Bozec, S., Vial, G., Kergoat, M., Fouqueray, P., Bolze, S., Borel, A., Fontaine, E., & Moller, D. E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-12-29
- Volume
- 23
- Issue
- 3
- Pages
- 664-673
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3109659757
- Cited by
- 198
- References
- 25
- FWCI
- 12.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.